Faraday Future在Qualigen投资4100万美元,重塑CXC10和Web3,获得62%的控制权。 Faraday Future invests $41M in Qualigen to rebrand it CXC10 and pivot to Web3, gaining 62% control.

Faraday Future通过该公司及其首席执行官YT Jia领导的PIPE交易,对Qualigen治疗(QLGN)进行了4 100万美元的战略性投资,以推进加密和网络3倡议。 Faraday Future has made a $41 million strategic investment in Qualigen Therapeutics (QLGN) via a PIPE transaction, led by the company and its CEO YT Jia, to advance crypto and Web3 initiatives. 这项交易,在股东批准前,将把QLGN重新命名为CXC10,并将其重点从生物制药转向数字创新。 The deal, pending shareholder approval, will rebrand QLGN as CXC10 and shift its focus from biopharmaceuticals to digital innovation. Faraday Future and Jia将集体拥有超过62%的QLGN共同股份, Faraday Future and Jia will collectively own over 62% of QLGN’s common stock, with key leadership roles assigned to FF executives. 这一交易使Faraday Future能够专注于电动车辆,同时在Sign Foundation、Sequoia Capital、IDG和Circle等投资者的支持下孤立其数字企业。 The transaction allows Faraday Future to concentrate on electric vehicles while isolating its digital ventures, supported by investors including SIGN Foundation, Sequoia Capital, IDG, and Circle. 该伙伴关系旨在通过跨技术生态系统的战略协同增效创造长期价值。 The partnership aims to create long-term value through strategic synergies across technology ecosystems.